Our specialized units cover diverse therapeutic areas such as endocrinology, metabolic disorders, cardiology, gastroenterology, women’s health, dermatology, hematology, and nephrology.
Mannheim, Germany – 29. January, 2025
CRS Clinical Research Services is pleased to announce its acquisition by hVIVO Services Limited (“hVIVO”), a rapidly growing specialist CRO and world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials.
The deal marks a significant milestone in CRS’ journey as we join a leading player in the global CRO sector, hVIVO. As part of the hVIVO Group, we will offer expanded services to accelerate clinical trials, including:
CRS Berlin will continue to operate as an independent site. CRS Mannheim and CRS Kiel are commited to maintaining a strong partnership with the Berlin Unit as a trusted collaborator and preferred vendor for specialized clinical trials, ensuring seamless support and business continuity for our clients. The existing senior leadership team will remain in place to ensure consistent delivery of our high-quality services and no changes are foreseen for the current study teams.
hVIVO is a UK headquartered CRO and the world leader in human challenge trials. The hVIVO Group also provides specialist drug development and clinical consultancy services via Venn Life Science (located in France and the Netherlands), virology and immunology laboratory services via hLAB, and clinical field trial services such as patient recruitment and clinical trial site services.
This acquisition represents a significant milestone in our commitment to delivering innovative, high-quality solutions for our clients.
With combined expertise, resources, and global reach, CRS is poised to offer even more comprehensive services and drive advancements in clinical trials.
Together, we look forward to shaping the future of clinical research and continuing our mission to improve patient outcomes worldwide.
Stay tuned for more updates as we embark on this new chapter.